Molecular Profile Detail

Profile Name SMO W535L
Gene Variant Detail

SMO W535L (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
SMO W535L Advanced Solid Tumor resistant Vismodegib Preclinical - Cell culture Actionable In a preclinical study, mouse fibroblast cells expressing human SMO W535L were resistant to Hedgehog pathway inhibition by Erivedge (vismodegib) in culture (PMID: 25801792). 25801792
SMO W535L Advanced Solid Tumor resistant Vismodegib Preclinical Actionable In a preclinical study, a transformed cell line expressing SMO W535L demonstrated resistance to Erivedge (vismodegib) (PMID: 25759020). 25759020
SMO W535L medulloblastoma sensitive Arsenic trioxide Preclinical Actionable In a preclinical study, treatment with arsenic trioxide resulted in improved survival in a transgenic mouse model of medulloblastoma expressing SMO W535L (PMID: 21183792). 21183792
SMO W535L Advanced Solid Tumor resistant Posaconazole Preclinical Actionable In a preclinical study, Posaconazole did not inhibit Hedghog signaling in mouse fibroblasts over expressing murine SMO W539L (corresponding to human SMO W535L) in culture (PMID: 26823493). 26823493
SMO W535L basal cell carcinoma predicted - sensitive Sonidegib Phase I Actionable In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in stable disease in a basal cell carcinoma patient harboring SMO W535L with resistance to Erivedge (vismodegib) (PMID: 26546616). 26546616
Clinical Trial Phase Therapies Title Recruitment Status